Literature DB >> 31306801

AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review.

Christopher L Bowlus1, Joseph K Lim2, Keith D Lindor3.   

Abstract

DESCRIPTION: The purpose of this clinical practice update is to define key principles in the surveillance of hepatobiliary cancers including cholangiocarcinoma, gallbladder adenocarcinoma, and hepatocellular carcinoma in patients with primary sclerosing cholangitis (PSC).
METHODS: The recommendations outlined in this expert review are based on available published evidence including observational studies and systematic reviews, and incorporates expert opinion where applicable. BEST PRACTICE ADVICE 1: Surveillance for cholangiocarcinoma and gallbladder cancer should be considered in all adult patients with PSC regardless of disease stage, especially in the first year after diagnosis and in patients with ulcerative colitis and those diagnosed at an older age. BEST PRACTICE ADVICE 2: Surveillance for cholangiocarcinoma and gallbladder cancer should include imaging by ultrasound, computed tomography, or magnetic resonance imaging, with or without serum carbohydrate antigen 19-9, every 6 to 12 months BEST PRACTICE ADVICE 3: Endoscopic retrograde cholangiopancreatography with brush cytology should not be used routinely for surveillance of cholangiocarcinomas in PSC. BEST PRACTICE ADVICE 4: Cholangiocarcinomas should be investigated by endoscopic retrograde cholangiopancreatography with brush cytology with or without fluorescence in situ hybridization analysis and/or cholangioscopy in PSC patients with worsening clinical symptoms, worsening cholestasis, or a dominant stricture. BEST PRACTICE ADVICE 5: Fine-needle aspiration of perihilar biliary strictures should be used with caution in PSC patients considered to be liver transplant candidates because of concerns for tumor seeding if the lesion is a cholangiocarcinoma. BEST PRACTICE ADVICE 6: Surveillance for cholangiocarcinoma should not be performed in PSC patients with small-duct PSCs or those younger than age 20. BEST PRACTICE ADVICE 7: The decision to perform a cholecystectomy in PSC patients with a gallbladder polyp should be based on the size and growth of the polyp, as well as the clinical status of the patient, with the knowledge of the increased risk of gallbladder cancer in polyps greater than 8 mm. BEST PRACTICE ADVICE 8: Surveillance for hepatocellular carcinoma in PSC patients with cirrhosis should include ultrasound, computed tomography, or magnetic resonance imaging, with or without α-fetoprotein every 6 months.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31306801     DOI: 10.1016/j.cgh.2019.07.011

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  14 in total

Review 1.  Guideline review: British Society of Gastroenterology/UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis.

Authors:  Alberto Nicoletti; James B Maurice; Douglas Thorburn
Journal:  Frontline Gastroenterol       Date:  2020-03-02

2.  Is it time for recommendations to reflect reality in PSC surveillance?

Authors:  James Hawken; Gautham Appanna; A J Portal
Journal:  Frontline Gastroenterol       Date:  2021-03-23

3.  Hepatocellular carcinoma in primary sclerosing cholangitis and primary biliary cholangitis: a clinical and pathological study in an uncommon but emerging setting.

Authors:  Dustin E Bosch; Yoh Zen; Sarag A Boukhar; Yongjun Liu; Lin Cheng; Matthew M Yeh
Journal:  Virchows Arch       Date:  2021-08-20       Impact factor: 4.064

Review 4.  Primary sclerosing cholangitis: review for radiologists.

Authors:  Matthew A Morgan; Rachita Khot; Karthik M Sundaram; Daniel R Ludwig; Rashmi T Nair; Pardeep K Mittal; Dhakshina M Ganeshan; Sudhakar K Venkatesh
Journal:  Abdom Radiol (NY)       Date:  2022-09-05

Review 5.  An Overview on Primary Sclerosing Cholangitis.

Authors:  Cătălina Vlăduţ; Mihai Ciocîrlan; Dana Bilous; Vasile Șandru; Mădălina Stan-Ilie; Nikola Panic; Gabriel Becheanu; Mariana Jinga; Raluca S Costache; Daniel O Costache; Mircea Diculescu
Journal:  J Clin Med       Date:  2020-03-11       Impact factor: 4.241

Review 6.  Management of primary sclerosing cholangitis and its complications: an algorithmic approach.

Authors:  Michal Prokopič; Ulrich Beuers
Journal:  Hepatol Int       Date:  2020-12-30       Impact factor: 6.047

7.  Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland.

Authors:  Nina Barner-Rasmussen; Eero Pukkala; Kishor Hadkhale; Martti Färkkilä
Journal:  United European Gastroenterol J       Date:  2021-09-17       Impact factor: 4.623

8.  Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis.

Authors:  John E Eaton; Christopher L Welle; Zeinab Bakhshi; Shannon P Sheedy; Ilkay S Idilman; Gregory J Gores; Charles B Rosen; Julie K Heimbach; Timucin Taner; Denise M Harnois; Keith D Lindor; Nicholas F LaRusso; Andrea A Gossard; Konstantinos N Lazaridis; Sudhakar K Venkatesh
Journal:  Hepatology       Date:  2021-04-19       Impact factor: 17.425

9.  Reporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group.

Authors:  Sudhakar K Venkatesh; Christopher L Welle; Frank H Miller; Kartik Jhaveri; Kristina I Ringe; John E Eaton; Helen Bungay; Lionel Arrivé; Ahmed Ba-Ssalamah; Aristeidis Grigoriadis; Christoph Schramm; Ann S Fulcher
Journal:  Eur Radiol       Date:  2021-08-06       Impact factor: 5.315

Review 10.  Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities.

Authors:  Mette Vesterhus; Tom Hemming Karlsen
Journal:  J Gastroenterol       Date:  2020-03-28       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.